Comparison of the efficacy and safety of moclobemide and imipramine in the treatment of depression in Indian patients | Zendy

Ajit Avasthi | Zendy; Parmanand Kulhara | Zendy; Gagandeep Singh | Zendy; Rajni Sharma | Zendy; RajinderP Kaur | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Comparison of the efficacy and safety of moclobemide and imipramine in the treatment of depression in Indian patients

Author(s) -

Ajit Avasthi,

Parmanand Kulhara,

Gagandeep Singh,

Rajni Sharma,

RajinderP Kaur

Publication year - 2005

Publication title -

indian journal of psychiatry

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.485

H-Index - 34

eISSN - 1998-3794

pISSN - 0019-5545

DOI - 10.4103/0019-5545.55951

Subject(s) - moclobemide , tolerability , antidepressant , monoamine oxidase a , monoamine oxidase inhibitor , imipramine , psychology , medicine , pharmacology , monoamine oxidase , adverse effect , chemistry , serotonin , biochemistry , receptor , alternative medicine , pathology , hippocampus , enzyme

Moclobemide, a benzamide, is one of the new-generation monoamine oxidase-A inhibitors (MAO-AIs) which belongs to the class of reversible inhibitors of monoamine oxidase (RIMA). Numerous studies have shown that moclobemide is well-tolerated and as effective as other antidepressants. So far, there is no evidence available regarding its efficacy and tolerability in India.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research